Overview of the 3rd isirv-Antiviral Group Conference--advances in clinical management.
This review highlights the main points which emerged from the presentations and discussions at the 3rd isirv-Antiviral Group Conference - advances in clinical management. The conference covered emerging and potentially pandemic influenza viruses and discussed novel/pre-licensure therapeutics and currently approved antivirals and vaccines for the control of influenza. Current data on approved and novel treatments for non-influenza respiratory viruses such as MERS-CoV, respiratory syncytial virus (RSV) and rhinoviruses and the challenges of treating immunocompromised patients with respiratory infections was highlighted.
WHO Collaborating Centre for Reference and Research on Influenza, VIDRL at the Peter Doherty Institute for Infection and Immunity, Parkville, Vic., Australia; Melbourne School of Population and Global Health, University of Melbourne, Parkville, Vic., Australia.
Aeron C
AC
Hurt
David S
DS
Hui
Alan
A
Hay
Frederick G
FG
Hayden
D000998:Antiviral Agents / Q000627:therapeutic use*; D021821:Communicable Diseases, Emerging; D018352:Coronavirus Infections / Q000188:drug therapy / Q000453:epidemiology; D006801:Humans; D016867:Immunocompromised Host; D007252:Influenza Vaccines; D007251:Influenza, Human / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control / Q000821:virology; D065207:Middle East Respiratory Syndrome Coronavirus; D058873:Pandemics; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy / Q000453:epidemiology; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control / Q000821:virology; D014777:Virus Diseases / Q000188:drug therapy / Q000453:epidemiology / Q000821:virology
D000998:Antiviral Agents; D007252:Influenza Vaccines
Antivirals; clinical management; immunocompromised; influenza; respiratory; treatment